Galderma Unveils Final Nine-Month Data Showing Lasting Efficacy and Patient Satisfaction With Its Injectable Aesthetics Portfolio When Addressing Facial Aesthetic Changes After Medication-Driven Weight Loss
Following interim analysis at three months presented earlier this year, a six-month extension study was conducted to capture the durability of treatment effects after nine months1
Galderma continues to lead the response to addressing the aesthetic concerns of patients experiencing medication-driven weight loss, leveraging its deep dermatological expertise and working closely with healthcare professionals to meet evolving patient needs
ZUG, Switzerland, July 17, 2025--(BUSINESS WIRE)--Galderma has revealed positive final data from a phase IV first-of-its-kind trial exploring the benefits of Restylane Lyft or Contour in combination with Sculptra to address the aesthetic concerns of patients experiencing facial volume loss associated with medication-driven weight loss.1 These data reinforce that this treatment regimen can effectively improve facial aesthetic appearance with high patient satisfaction over nine months.1
Rates of medication-driven weight loss have increased rapidly in recent years and can be associated with facial alterations of variable magnitude.2-4 Patients may experience facial changes such as dry, dull or sagging skin, a gaunt or hollowed-out facial appearance, or other unwelcome alterations to facial structure and balance.3,4 As the pure-play dermatology category leader, Galderma is spearheading efforts to identify and address the most predominant aesthetic concerns of patients along their weight loss journey.
"At Galderma, we are leading the charge in redefining aesthetic care for patients impacted by medication-driven weight loss. Our commitment is clear: to empower individuals to reclaim their confidence through cutting-edge, data-driven innovation and strategic collaboration with the world's foremost experts, and these latest study results reinforce this mission."
FLEMMING ØRNSKOV, M.D., MPHCHIEF EXECUTIVE OFFICERGALDERMA
In the phase IV clinical study conducted in the U.S., Galderma investigated the aesthetic outcomes and appearance, and patient satisfaction of Restylane Lyft or Contour in combination with Sculptra for cheek or jawline augmentation and correction of contour deficiencies in patients experiencing facial volume loss associated with medication-driven weight loss.1 The trial used the SHAPE Up Holistic Individualized Treatment (HIT™) – an individualized treatment approach which enables injectors to leverage their expertise with Galderma's Sculptra and its Restylane portfolio to optimize aesthetic outcomes while prioritizing patient satisfaction.
Patients were treated with Sculptra and either Restylane Lyft or Contour for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyft or Contour at Week 4, and an optional third treatment of Sculptra at Week 8.1
Following interim analysis at three months presented earlier this year, a six-month extension study was conducted to capture the durability of treatment effects after nine months. In the extension study, follow-up visits took place at Weeks 32 and 44 for those who received the third Sculptra treatment and at Weeks 28 and 40 for those who did not, corresponding to nine months after their first Sculptra treatment.1
Results at nine months demonstrated that the combination of Sculptra and Restylane Lyft or Contour effectively improved the aesthetic appearance of patients experiencing facial volume loss associated with medication-driven weight loss, further supporting the benefits of the SHAPE Up HIT:1
The combined Sculptra and Restylane Lyft or Contour regimen demonstrated skin quality improvements, with Restylane improving skin hydration and Sculptra significantly improving skin radiance through to Month 91
Subject satisfaction – which was reported by the majority of patients as early as Week 4 – was maintained through to Month 9:1
85.7% of patients said their face looked less gaunt/sunken1
88.6% said they "loved" how the treatment maintained their facial structure1
88.6% of patients said they "loved" the regenerative effects of Sculptra treatment1
88.6% felt they looked better than before the injection regimen1
91.4% said they would recommend the injection regimen to others after weight loss and to those with loose, sagging facial skin1
Safety was in line with previous pivotal trial data for Sculptra, Restylane Lyft and Contour, with no treatment-related adverse events reports.1
"The improvements we observed with Sculptra and Restylane at nine months are hugely encouraging and represent a meaningful step forward in addressing the most predominant aesthetic concerns of patients along their weight loss journey. It was exciting to see the glow we've clinically observed in the past with Sculptra now validated through innovative bioinstrumentation tools in this study. For physicians and patients who are navigating the visible effects of medication-driven weight loss, this study delivers real, evidence-based solutions that can make a tangible difference to how individuals look and feel."
Z. PAUL LORENC, M.D.CLINICAL TRIAL INVESTIGATORNEW YORK, UNITED STATES
"These results really reinforce the role of aesthetic treatments, like Sculptra and Restylane, in supporting patients through their weight loss transformations, showing they can deliver visible improvements in skin quality while also significantly enhancing patient satisfaction and emotional wellbeing. The findings empower clinicians with data-backed tools to holistically address the nuanced aesthetic needs that arise with medication-driven weight loss, marking a pivotal moment where science meets patient-centered care."
MICHAEL SOMENEK, M.D.CLINICAL TRIAL INVESTIGATORWASHINGTON DC, UNITED STATES
Galderma is spearheading multiple additional initiatives to identify and address the most predominant aesthetic concerns of patients who have experienced medication-driven weight loss through data-driven, innovative approaches in close collaboration with leading healthcare practitioners, as outlined in the company's recent report.5 Galderma has supported pioneering research in the field, including the first recently published international consensus-based guidelines that provide a practical framework for practitioners to address the aesthetic needs of medication-driven weight loss patients, as well as research into the impact of medication-driven weight loss on the skin and the importance of factoring in aesthetic treatment goals during the patient journey.6
*Restylane Contour is known as Restylane® Volyme™ in countries outside of the U.S.
About the studyThis phase IV trial was a multi-center, open-label study to evaluate the synergistic effects of Restylane Lyft or Contour in combination with Sculptra for cheek augmentation and correction of contour deficiencies, in patients experiencing facial volume loss following treatment with one of four brands of glucagon-like peptide-1 (GLP-1) receptor agonists.1 Conducted in the U.S., the trial took place across two sites, and used the SHAPE Up Holistic Individualized Treatment (HIT) as a treatment methodology, with patients treated with Sculptra and either Restylane Lyft or Contour for their first treatment, a second treatment of Sculptra with an optional touch-up of Restylane Lyft or Contour at Week 4, and an optional third treatment of Sculptra at Week 8.1
About GaldermaGalderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References
Galderma. Data on file. Somenek M and Lorenc P. A multi-center, open-label study to evaluate the synergistic effects of biostimulator and dermal fillers for cheek augmentation and correction of contour deficiencies: Nine-month topline results.
Mansour MR, et al. The rise of "Ozempic Face": Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists. JPRAS. 2024;96:225-227. doi: 10.1016/j.bjps.2024.07.051
Tay JQ. Ozempic face: A new challenge for facial plastic surgeons. JPRAS. 2023;81:97-98. doi: 10.1016/j.bjps.2023.04.057
Humphrey CD and Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39:719-721. doi: 10.1055/a-2148-6321
Galderma. Balancing The Scales: Advancing Aesthetics In The Era Of Medication-driven Weight Loss Transformations. July 2025. Available online
Nikolis A, et al. Consensus Statements on Managing Aesthetic Needs in Prescription Medication-Driven Weight Loss Patients: An International, Multidisciplinary Delphi Study. JCD. 2025;24: e70094. https://doi.org/10.1111/jocd.70094
View source version on businesswire.com: https://www.businesswire.com/news/home/20250716698427/en/
Contacts
Christian Marcoux, M.Sc.Chief Communications Officerchristian.marcoux@galderma.com +41 76 315 26 50
Richard HarbinsonCorporate Communications Directorrichard.harbinson@galderma.com +41 76 210 60 62
Céline BuguetFranchises and R&D Communications Directorceline.buguet@galderma.com +41 76 249 90 87
Emil IvanovHead of Strategy, Investor Relations, and ESGemil.ivanov@galderma.com +41 21 642 78 12
Jessica CohenInvestor Relations and Strategy Directorjessica.cohen@galderma.com +41 21 642 76 43
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
INBRAIN Neuroelectronics Reports Interim Analysis of First-in-Human Study of Graphene Brain-Computer Interface
Graphene-based BCI demonstrates high-resolution brain decoding and mapping in patients undergoing tumor resection at the Manchester Centre for Clinical Neurosciences Initial four patient cohort has shown no safety concerns to date that would prevent the completion of this first-in-human study. BARCELONA, Spain, July 29, 2025--(BUSINESS WIRE)--INBRAIN Neuroelectronics today announced the interim analysis of findings from the world's first-in-human clinical study of its graphene-based brain-computer interface (BCI) technology. The study, sponsored by the University of Manchester and conducted at the Manchester Centre for Clinical Neurosciences (Northern Care Alliance NHS Foundation Trust), is evaluating the safety and functional performance of graphene-based electrodes when used during surgery for resection of brain tumors. The primary objective of the study (NCT06368310) is to assess the safety of INBRAIN's brain-computer interface (BCI) during brain tumor surgery. Secondary objectives include evaluating the quality of neural signals captured by the device, its ability to deliver targeted brain stimulation, the consistency of its performance throughout the procedure, and its overall suitability for use in the neurosurgical operating room. A total of 8 to 10 patients are expected to be enrolled to validate the safety and functional performance of the graphene-based BCI. The study design included an interim analysis after the first four patients had been recruited to ensure patient safety and data quality. Interim analysis of the results from the first cohort of four patients enrolled in the study demonstrated no device-related adverse events, a key component of the primary endpoint of the study. During awake language mapping, the device captured distinct high gamma activity linked to different phonemes, the smallest units of sound in speech, showcasing exceptional spatial and temporal resolution, even with micrometer-scale contacts. The ultra-thin, sub-micrometer graphene electrodes also proved compatible with commercially available, CE-marked electrophysiology systems, reliably recording real-time brain signals throughout the surgical procedures. "The ability to detect high-frequency neural activity with micrometer-scale precision opens new possibilities for understanding brain-tumor interactions and broader brain function in neuro-related disorders," said Mr. David Coope, Chief Investigator and Consultant Neurosurgeon at the Manchester Centre for Clinical Neurosciences, the Geoffrey Jefferson Brain Research Centre and the University of Manchester. "This technology could be transformative, not only for improving surgical outcomes but for unlocking new treatment pathways." Throughout the procedures, INBRAIN's BCI enabled high-resolution brain signal monitoring, addressing one of the most pressing challenges in neurosurgery: achieving precise tumor removal while preserving essential functions such as speech, movement, and cognition. The device was used in parallel with standard clinical monitoring tools, maintaining consistent performance across the surgical window. "This milestone demonstrates that graphene-based brain-computer interfaces can be deployed in the operating room and deliver a level of neural fidelity not achievable with traditional materials," said Carolina Aguilar, CEO and Co-Founder, INBRAIN Neuroelectronics. "We're moving toward a future where neurosurgeons and neurologists can rely on real-time, high-definition brain data to guide personalized interventions." INBRAIN's platform is powered by ultra-flexible, thin-film graphene semiconductors that conform more precisely to the brain surface than conventional strip electrodes. The BCI features high-density, multiscale, bidirectional contacts for superior decoding and modulation, and reduced graphene oxide (rGO) nanoporous matrices that enhance sensitivity and signal resolution. In preclinical studies, the GCI significantly outperformed platinum-based electrodes in detecting high gamma frequencies (80–130 Hz) critical for speech decoding, with statistical significance (p < 0.01). Clinical Advantages Graphene technology offers several benefits for neurosurgical procedures. It enhances surgical precision by enabling smaller and more densely packed electrodes, allowing surgeons to define and preserve critical functional areas during tumor resection. Its flexibility enables accurate decoding and mapping in anatomically complex or hard-to-access brain regions, including the walls of the tumor resection cavity. Additionally, the device's ability to decode high-frequency activity offers huge scientific opportunities including the potential to reveal in situ interactions between glioma cells and neurons, offering potential insights into new therapeutic targets for halting tumor progression. "We're not delivering incremental innovation, we're enabling entirely new capabilities," said Kostas Kostarelos, Co-Founder of INBRAIN and Chief Scientific Investigator of the study and Professor of Nanomedicine at the University of Manchester, the Catalan Institute of Nanoscience and Nanotechnology (ICN2) in Barcelona, and Programme Lead for the Next Generation Therapeutics Theme of the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC). "This convergence of advanced materials science, neuroscience, and AI is shaping the future of real-time, precision neurology." As the first safety study of a graphene-based neural interface in humans, this study marks a foundational step toward the development of BCI therapeutic systems for chronic neurological diseases, pioneering a new era of real-time, precision neurology. About INBRAIN Neuroelectronics INBRAIN Neuroelectronics is pioneering real-time precision neurology with the world's first graphene-based brain-computer interface (BCI) therapeutics platform. Our technology combines precise BCI decoding with micrometric modulation to deliver adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By providing continuous real-time monitoring and autonomous therapy adjustments, our AI-driven platform maximizes therapeutic outcomes while minimizing side effects. Through strategic collaborations, including with Merck KGAa and our subsidiary INNERVIA Bioelectronics, we are extending our innovative solutions to peripheral nerve and systemic disease applications, unlocking the potential of neurotechnology and bioelectronics. For more information, visit and follow us on LinkedIn. About Northern Care Alliance (NCA) Northern Care Alliance NHS Foundation Trust provides hospital and community healthcare services in Salford, Oldham, Bury and Rochdale. Our dedicated team of around 20,000 staff delivers high standards of care and experience excellence to over one million people across Greater Manchester and beyond, working together to save lives and improve lives. More information about the NCA can be found at About the National Institute for Health and Care Research (NIHR) The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by: Funding high quality, timely research that benefits the NHS, public health and social care; Investing in world-class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services; Partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research; Attracting, training and supporting the best researchers to tackle complex health and social care challenges; Collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system; Funding applied global health research and training to meet the needs of the poorest people in low and middle income countries. NIHR is funded by the Department of Health and Social Care. Its work in low and middle income countries is principally funded through UK international development funding from the UK government. About the NIHR Manchester Biomedical Research Centre (BRC) The NIHR Manchester Biomedical Research Centre (BRC) transforms scientific breakthroughs into diagnostic tests and life-saving treatments for patients. NIHR Biomedical Research Centres (BRCs) are collaborations between NHS organisations and universities. They bring together academics and clinicians to translate scientific discoveries into potential new treatments, diagnostics and technologies. Manchester BRC is hosted by Manchester University NHS Foundation Trust and The University of Manchester – in partnership with five NHS trusts; Blackpool Teaching Hospitals NHS Foundation Trust, The Christie NHS Foundation Trust, Greater Manchester Mental Health NHS Foundation Trust, Lancashire Teaching Hospitals NHS Foundation Trust, and the Northern Care Alliance NHS Foundation Trust. About The University of Manchester The University of Manchester is recognised globally for its pioneering research, outstanding teaching and learning, and commitment to social responsibility. The Russell Group institution is ranked the 6th best university in the UK and 38th in the world (Academic Ranking of World Universities). A truly international university, its community includes more than 44,000 students, 12,000 staff, and 500,000 alumni from 190 countries. Together, they are tackling the world's biggest challenges – the University's social and environmental impact is ranked in the top ten globally (Times Higher Education Impact Rankings). The University is a powerhouse of research and discovery; 25 Nobel laureates are among its former staff and students; and it was ranked fifth for research power – the quality and scale of research and impact – in the UK government's Research Excellence Framework (REF) 2021. The institution is the most popular in the UK for undergraduate applications (UCAS 2021 cycle), and it is the it is the most targeted university by the UK's leading employers (The Graduate Market, 2023). View source version on Contacts Media Kimberly HaKKH Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
AstraZeneca PLC (AZN) Announced Positive Results for its Phase 3 Trial of Gefurulimab
AstraZeneca PLC (NASDAQ:AZN) is one of the . On July 24, AstraZeneca PLC (NASDAQ:AZN) announced positive results for its global Phase 3 trial of Gefurulimab in adults with generalized myasthenia gravis who are antibody-positive. Management noted that the trial was randomized, double-blind, and placebo-controlled. It met its primary and all secondary endpoints as patients showed significant improvement in their daily activities related to gMG at 26 weeks compared to placebo. gMG is a rare autoimmune disease that causes muscle weakness and loss of function. CEO of AstraZeneca PLC (NASDAQ:AZN) Rare Disease Marc Dunoyer noted that the results confirm gefurulimab's potential as a fast-acting and sustained treatment option. Management expects the treatment to become first-line with a good safety profile. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that focuses on oncology, rare diseases, cardiovascular, respiratory, immunology, and vaccines. While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
2 hours ago
- Yahoo
Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze
NeuroX recently acquired the assets and operations of MindMaze, a world-renowned leader in evidence-based neurotherapeutic solutions for neurological diseases and brain disorders Business combination to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech company Binding term sheet signed; transaction subject to customary conditions and approvals Closing expected in Q4 2025 GENEVA, SWITZERLAND / / July 29, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) ("Relief" or the "Company"), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the execution of a binding term sheet for a proposed business combination with NeuroX Group SA ("NeuroX"), a privately held company that recently acquired the assets and operations of MindMaze - a recognized leader in digital neurotherapeutics and brain health technologies. The envisaged combination aims to create a publicly listed, AI-based therapeutics platform integrating software-delivered, disease-modifying clinical interventions with pharmacological treatments and a comprehensive brain health platform to improve the quality of life of patients, caregivers and families. NeuroX will contribute a clinically validated, risk-mitigated portfolio supported by multiple milestones achieved across technological development, regulatory approvals, and market access, as well as a solid network of pharmaceutical partners. Dr. Raghuram Selvaraju, chairman of the board of directors of Relief, commented: "By entering into this transaction, we intend to bring a global pioneer in digital neurotherapeutics to the public markets through the Relief ecosystem. NeuroX, which now operates the MindMaze platform, has a compelling business model, an established track record of innovation, and a distinctive technology that integrates neuroscience and digital therapeutics to address some of the most pressing challenges in neurology. We believe this combination has the potential to create significant value for patients, clinicians, and shareholders. Importantly, it offers existing Relief shareholders the opportunity to participate in the growth of a scalable enterprise with potential to become a multi-billion-dollar company." Alexandre Capet, head of corporate development of NeuroX, commented: "The business combination with Relief presents a timely opportunity to build on the vision and ambition set by MindMaze on a global scale, accelerating our market presence and next phase of growth. Over the past decade, we have built a robust portfolio of clinically validated digital neurotherapeutics and invested heavily in commercial infrastructure, AI technology, and R&D. With increased visibility and a solid foundation in place, we believe this transaction comes at a pivotal inflection point in our journey. It positions us to scale more effectively as a publicly listed company and expand the reach of our breakthrough therapies." NeuroX and MindMaze OverviewNeuroX is a Swiss-based, commercial-stage company. In 2025, NeuroX acquired the operations and intellectual property of the legacy MindMaze group ("MindMaze"), including the MindMaze ® brand. MindMaze has developed first-of-its-kind neurotherapeutics that provide disease-modifying motor and cognitive treatments for neurological diseases and brain disorders. These neurotherapeutics are delivered through proprietary software and hardware, underpinned by an advanced brain technology platform that integrates wearables and sensors, and provides digital assessments as well as telehealth services. The unique suite of MindMaze solutions is delivered globally across the continuum-of-care, both in-clinic and in patients' home, to successfully address some of neurology's major unmet needs. NeuroX has already partnered with leading pharmaceutical companies that use its proprietary technology across multiple clinical trials. Over the last decade, MindMaze has invested more than USD 350 million to establish clinical evidence, demonstrate significant medico-economic outcomes, and market MindMaze's disease-modifying therapeutic platform across neurological diseases, including stroke, Parkinson's disease, and at-risk aging. In the United States, MindMaze has received a unique reimbursement code (CAT-3) to support the delivery of its home-based neurotherapeutic training. Its R&D pipeline focuses on adjacent neurological diseases, such as spinal cord injury, multiple sclerosis, traumatic brain injury, and Alzheimer's disease/dementia. Moved by the mission to accelerate the brain's ability to recover, the MindMaze platform innovates by combining software-delivered behavioral treatments, drugs, devices, data, and AI to establish a new paradigm of precision medicine in neurology and neural repair. For more information, visit . Transaction OverviewUnder the terms of the term sheet, NeuroX shareholders will exchange at closing all outstanding shares of NeuroX for newly issued shares of Relief. The transaction is based on agreed equity valuations of CHF 100 million for Relief, representing a significant premium to its current market capitalization, and CHF 1 billion for NeuroX. Post-closing, Relief shareholders are expected to own approximately 9% of the combined entity on a fully diluted basis, with NeuroX shareholders holding the remaining 91%. The combined entity's shares will continue trading on the SIX Swiss Exchange. The term sheet provides for full exclusivity during the negotiation and finalization of a definitive agreement, as well as a customary break fee, reflecting the commitment of both parties to advance the transaction. It also includes a one-year post-closing reset mechanism to adjust the ownership ratio within certain parameters based on the combined entity's market value at that time. The transaction remains subject, among other customary conditions, to the negotiation and execution of a definitive agreement, completion of satisfactory due diligence, approval by the shareholders of both companies, completion of concurrent financing by NeuroX, filing of regulatory documentation with the applicable securities authorities, and receipt of regulatory and stock exchange approvals. There can be no assurance that the transaction will be completed on the terms described herein or at all. The parties expect to finalize the definitive transaction agreement in Q3 2025, with closing anticipated in Q4 2025. ABOUT RELIEFRelief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief's clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. The Company has access to a CHF 50 million equity commitment in the form of a share subscription facility with its largest shareholder, Global Emerging Markets (GEM). For more information, visit CONTACTRELIEF THERAPEUTICS Holding SAJeremy MeinenChief Financial Officercontact@ DISCLAIMERThis press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise. The information provided on NeuroX and MindMaze within this press release is provided by NeuroX. Relief makes no representation or warranty as to the accuracy, completeness, or reliability of such information and disclaims any obligation or liability in connection with it. No offer or solicitation: This press release does not constitute (i) a prospectus within the meaning of the Swiss Financial Services Act or under any other applicable laws, (ii) a solicitation of proxy, consent or authorization with respect to any securities or in respect of the proposed business combination or (iii) an offer to sell, a solicitation of an offer to buy, or a recommendation to buy any security of Relief, NeuroX, or any of their respective affiliates. There shall not be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the laws of such other jurisdiction. This press release should not be treated as offering material of any sort and is for information purposes only. SOURCE: Relief Therapeutics Holding SA View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
